KPV
Gut Health & ImmunityResearch-GradeLast reviewed: September 26, 2026
Quick Facts
- What it is
- The C-terminal tripeptide of α-MSH (lysine-proline-valine) — a small, cell-penetrating fragment studied for anti-inflammatory effects in gut/IBD, skin conditions, and wound healing.
- How it's taken
- Subcutaneous injection, oral capsule, or topical — route depends on the target (oral for gut, topical for skin, subQ for systemic)
- Half-life
- Under 1 hour (plasma); effects persist via gene-expression changes
- Typical research dose
- 250 mcg–1 mg daily, in 4–8 week cycles
- Research status
- Not FDA-approved — research use only.
On this page
- 1.Where to source KPV
- 2.What is KPV?
- 3.How does KPV work?
- 4.What is KPV used for?
- 5.How long does KPV take to work?
- 6.How is KPV dosed?
- 7.How is KPV administered?
- 8.What does KPV stack well with?
- 9.What are the side effects of KPV?
- 10.Does KPV interact with other drugs?
- 11.How should KPV be stored?
- 12.What are the limitations of KPV research?
- 13.KPV FAQ
- 14.References
- 15.Published Studies
- 16.In the News
Where to source KPV
KPV is not FDA-approved and is sold by specialty research peptide vendors as oral capsules, injectable lyophilized powder, or topical formulations. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes — including an oral-capsule option that's unusually well-suited to KPV's gut applications.
ILS Laboratories · batch COAs
Kovera, Chromate and BioRegen · certificates checked at each lab
Batch-traceable COAs · cold-chain shipping
Also stocking KPV
Fusion Peptide, GenPeptide, Healius Peptides, Ignite Peptides — each carries a current price row for this compound.
What is KPV?
KPV — also written as the KPV tripeptide or α-MSH (11–13) — is a small tripeptide (lysine-proline-valine) derived from the C-terminal sequence (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH). Despite its size, KPV exhibits potent anti-inflammatory and antimicrobial activity through pathways distinct from larger immune peptides. It has emerged as a research compound of interest for inflammatory bowel disease (IBD), ulcerative colitis, atopic dermatitis, and other inflammation-driven conditions. KPV's small size allows it to penetrate cells and act intracellularly, where it inhibits NF-κB signaling and reduces pro-inflammatory cytokine production. Often paired with BPC-157 for gut applications, or used as part of the KLOW blend (KPV + GHK-Cu + BPC-157 + TB-500) for broader regenerative protocols. New to peptide research? Start with the basics
Reported benefits:
- Anti-inflammatory effects through NF-κB pathway inhibition
- Reduced inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta)
- Antimicrobial activity against bacterial, fungal, and yeast infections
- Mucosal healing in inflammatory bowel models
- Skin inflammation reduction (atopic dermatitis, psoriasis research)
- Often combined with BPC-157 in compounded blends for gut applications
Common research dose: Oral capsules (compounded): 250–500 mcg daily. Subcutaneous injection: 200–500 mcg once daily. Some protocols use up to 1 mg daily for active inflammatory conditions. Topical formulations (creams) used for skin applications.
Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.
How does KPV work?
KPV penetrates cells and inhibits NF-κB nuclear translocation — the master regulator of inflammatory gene expression. This reduces pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and provides direct antimicrobial activity. Despite being derived from α-MSH (parent of Melanotan II and PT-141), KPV's anti-inflammatory effects do NOT involve melanocortin receptor activation — the 3-amino-acid fragment lacks the receptor-binding domain.
- NF-κB Pathway Inhibition [1]. KPV penetrates cells and directly inhibits NF-κB nuclear translocation, the master regulator of inflammatory gene expression. This is the primary mechanism behind its anti-inflammatory effects.
- Cytokine Reduction [2]. Reduces pro-inflammatory cytokines TNF-alpha, IL-6, IL-1beta, and IL-8 in research models. Effects observed in colonic tissue, dermal fibroblasts, and immune cells.
- Antimicrobial Activity [3]. Direct antimicrobial effect against S. aureus, E. coli, and Candida albicans. Mechanism distinct from antibiotic pathways — does not promote resistance development.
- Melanocortin-Independent. Despite being derived from α-MSH, KPV's anti-inflammatory effects do NOT require melanocortin receptor activation. The tripeptide acts intracellularly through a separate mechanism.
- Mucosal Tissue Localization [4]. Particular activity in colonic epithelium and intestinal mucosa, supporting research interest in IBD applications. PepT1-mediated uptake concentrates KPV in inflamed gut tissue.
What is KPV used for?
KPV's research evidence base centers on inflammatory bowel disease (IBD), atopic dermatitis and skin inflammation, wound healing, and antimicrobial research. The IBD evidence in animal models is the strongest area, with PepT1-mediated uptake concentrating KPV at inflamed gut tissue. The KLOW blend (KPV + GHK-Cu + BPC-157 + TB-500) is the most popular commercial form for combined regenerative + anti-inflammatory protocols.
- Inflammatory Bowel Disease [5]. Multiple animal studies show KPV reduces colitis severity in DSS and TNBS-induced colitis models. Reduced histological damage, improved mucosal healing, decreased inflammatory infiltration. Particle-based delivery systems explored to target inflamed intestinal tissue.
- Atopic Dermatitis & Skin Inflammation. Topical KPV formulations studied for inflammatory skin conditions. Reduced inflammatory markers and improved barrier function in research models.
- Wound Healing. Anti-inflammatory contribution to wound healing in research models. Often combined with BPC-157, TB-500, or GHK-Cu in compounded formulations.
- Antimicrobial Research [3]. Activity against drug-resistant bacterial strains. Studied as adjunct to traditional antibiotics in research contexts.
- KLOW Blend. Compounded blend combining KPV with GHK-Cu, BPC-157, and TB-500 (typical 50/10/10/10 mg ratio). Most popular commercial form for combined regenerative + anti-inflammatory protocol.
How long does KPV take to work?
KPV effects develop on multiple timescales. Acute anti-inflammatory effects are measurable within hours of dosing. Mucosal healing in IBD models takes 1–2 weeks. Skin inflammation improvements with topical use are sometimes reported within 2–4 weeks, though no trial or label has been identified establishing this timeframe. Most users assess KPV after 4–8 week protocols. Effects appear to be dose-dependent within the typical research range.
Acute anti-inflammatory effects are measurable within hours of dosing — KPV's intracellular NF-κB inhibition is fast-acting at the molecular level. Mucosal healing in IBD models takes 1–2 weeks of consistent dosing. Skin inflammation improvements with topical use typically appear in 2–4 weeks. Most users assess KPV after 4–8 week protocols. Effects appear to be dose-dependent within the typical research range (250 mcg to 1 mg daily).
How is KPV dosed?
No human trial of KPV has established a dose. The cited animal literature demonstrates anti-inflammatory efficacy in colitis models, but the numeric doses those studies administered sit behind a paywalled methods section and were not independently verified here. The figures below for oral, subcutaneous, and topical human use are entirely community convention, not derived from either cited study.
Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.
Need to calculate a dose?
Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.
Open CalculatorWhat the cited literature administered
Animal models (mouse colitis), evidence level: animal, specific dose not independently verified [2][5]. Kannengiesser et al. (Inflamm Bowel Dis, 2008, PMID 18092346) treated mice with KPV in two colitis models (DSS colitis and CD45RBhi transfer colitis), reporting earlier recovery, greater body-weight regain, and significantly reduced histological inflammation and colonic myeloperoxidase activity versus untreated controls, with no adverse findings reported in the paper’s own results. Xiao et al. (Mol Ther, 2017, PMID 28143741) delivered KPV orally to mice with induced ulcerative colitis using hyaluronic-acid-functionalized nanoparticles in a chitosan/alginate hydrogel, reporting stronger prevention of mucosal damage and greater TNF-α downregulation than an unfunctionalized KPV-nanoparticle formulation, and described the nanoparticles as nontoxic and biocompatible with intestinal cells in vitro. Both papers report the specific KPV dose administered in their methods sections, which are paywalled beyond the abstract; Prof. Peptide was not able to independently verify the numeric mg/kg (or equivalent) figure for either study, so none is stated here. Both are mouse efficacy studies, not human dosing trials, and neither has been identified as establishing a subcutaneous, oral-capsule, or topical dose in humans.
Community-reported practice (unverified)
Reported research-community practice — not independently verified by Prof. Peptide, and not derived from either animal study above — is 250–500 mcg orally once daily for general anti-inflammatory use, up to 500 mcg twice daily (1 mg/day total) for IBD-focused protocols, 200–500 mcg subcutaneously once daily for systemic use, or a 0.05–0.1% topical concentration applied once or twice daily for skin applications. This diverges from the cited animal studies in species (human versus mouse), dose basis (a flat mcg figure versus the studies’ own unpublished dosing), and in the oral case, delivery vehicle (a plain enteric-coated capsule versus the nanoparticle/hydrogel system the Xiao study actually tested) — no source was found deriving the community figures from either study’s numbers. A cycle length of 4–8 weeks active with a 2-week break is likewise reported community convention rather than something either cited study measured.
The KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV) is dosed at 0.25–0.5 mL of reconstituted blend, 5 days/week — see the KLOW page for blend protocol details.
The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.
How is KPV administered?
Vendors sell KPV as oral enteric-coated capsules, subcutaneous injection, or topical cream. The case for oral use rests on PepT1-mediated KPV uptake shown in cell lines and on oral KPV in drinking water reducing colitis in mice [4]; no human oral bioavailability or pharmacokinetic data exist. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.
- Oral capsules. Taken with or without food. Enteric coating typical for gut-targeted use — preserves the peptide through gastric acid for release in the intestine.
- Subcutaneous route. Rotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to KPV. Common for systemic anti-inflammatory effects rather than gut applications.
- Topical route. Reported applied to clean, dry skin 1–2× daily for skin inflammation research.
- Time of day. Any — no circadian timing requirement.
- Site rotation. For subcutaneous, use a different site each day.
- Missed dose. Reported practice skips and resumes the next day. The convention is not to double-dose.
- Cycle structure. 4–8 weeks active, 2-week break recommended.
Timing context. Community protocols use daily oral, subcutaneous, or topical dosing during a cycle. No human study has compared routes or timing. The gut rationale for oral use rests on cell-line PepT1 uptake and mouse drinking-water data [4]; no human oral pharmacokinetic data exist.
| Aspect | Reported |
|---|---|
| Frequency | Once or twice daily; a 4–8 weeks on, 2-week break cycle is reported community practice, not derived from a trial or label; Prof. Peptide has not independently verified it. |
| Best time of day | Any consistent time — no circadian timing requirement |
| Food | Oral: no restriction. Injectable: no restriction. Topical: clean, dry skin. |
| Route choice | Oral for gut; subQ for systemic; topical for skin |
| Half-life | A plasma half-life under 1 hour is commonly reported; biological effects are said to persist via gene-expression changes, though no published pharmacokinetic study or label has been identified establishing this figure for KPV. |
| Steady-state | Functional effects accumulate over the cycle; acute NF-κB inhibition is fast-acting at cellular level |
Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. KPV research vials are typically 5 mg. Because KPV doses are small (250–500 mcg per injection), 2 mL reconstitution is the common research convention — it gives clean whole-number units across the typical dose range. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial.
| BAC water | Concentration | 100 mcg dose | 250 mcg dose | 500 mcg dose | 1 mg dose |
|---|---|---|---|---|---|
| 1 mL | 5 mg/mL | 2 units | 5 units | 10 units | 20 units |
| 2 mL | 2.5 mg/mL | 4 units | 10 units | 20 units | 40 units |
| 3 mL | 1.67 mg/mL | 6 units | 15 units | 30 units | 60 units |
Units vs mcg. At a 5 mg vial, each unit drawn delivers 50 mcg of KPV at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.
What does KPV stack well with?
KPV pairs most naturally with BPC-157 for gut applications — its anti-inflammatory complements BPC-157's regenerative effect without mechanism overlap. The KLOW blend extends this pairing with GHK-Cu and TB-500 for a broader regenerative + anti-inflammatory protocol. KPV is also compatible with standard IBD-supportive protocols (probiotics, glutamine, omega-3). The main thing to clarify is what KPV is NOT — it doesn't activate melanocortin receptors despite the α-MSH origin, so it doesn't interact with PT-141 or Melanotan II.
- BPC-157. BPC-157 is the most common pairing for gut applications. KPV's anti-inflammatory + BPC-157's regenerative effects work through complementary mechanisms.
- KLOW Blend. The compounded all-in-one regenerative blend — KLOW (GHK-Cu + BPC-157 + TB-500 + KPV, typical 50/10/10/10 mg ratio) is the most popular commercial form.
- TB-500. TB-500 combined with KPV for inflammation + tissue repair research.
- Standard IBD-supportive protocols. Probiotics, glutamine, omega-3 — compatible. Mechanisms are non-overlapping.
- Conflicts: high-dose oral copper supplements during topical KPV use. Theoretical interaction with copper-binding proteins.
What are the side effects of KPV?
KPV's α-MSH-derived structure suggests low toxicity. The most-reported user effects are mild injection-site reactions (subcutaneous) or occasional GI changes (oral). No documented serious adverse events at standard doses, though long-term safety beyond 6 months is not formally characterized.
Common (most users)
- Mild injection site reactions. Subcutaneous route only.
- Occasional GI changes. Oral route — usually mild, often resolves as the gut adjusts.
Less common (moderate)
- Mild headache. Inconsistent across users.
- Mild fatigue. Inconsistent across users.
Serious (rare)
- Long-term safety beyond 6 months not formally characterized.
KPV's α-MSH-derived structure suggests low toxicity. NOT FDA-approved for any indication.
Does KPV interact with other drugs?
KPV has no documented major drug-drug interactions. NSAIDs and corticosteroids have additive anti-inflammatory effects and are generally compatible. Important clarification: KPV does NOT interact with PT-141 or Melanotan II despite the shared α-MSH origin — KPV lacks the melanocortin receptor-binding domain.
- NSAIDs and corticosteroids. Additive anti-inflammatory effects, generally compatible. The combined effect is what reported protocols watch when either dose changes.
- Immunosuppressants. Limited data on combination; theoretical additive immunomodulation.
- PT-141 / Melanotan II. A distinct mechanism from these melanocortin-receptor agonists: KPV does NOT activate MCR receptors, so the two are unrelated despite the shared α-MSH origin.
- No documented major drug interactions.
How should KPV be stored?
- Lyophilized: -20°C long-term, 2–8°C short-term.
- Reconstituted: 2–8°C, 30 days max.
- Oral capsules: room temperature, dry, dark.
- Topical formulations: refrigerate after opening.
- Reconstitution uses bacteriostatic water for injection. Swirl gently — do not shake.
- A solution that is cloudy, discolored, or contains particles is discarded.
What are the limitations of KPV research?
KPV is NOT FDA-approved for any indication. Despite its small molecular size and clean side-effect profile, it has not progressed through formal clinical trials. Most evidence is from animal models (colitis, dermatitis) and cell-based research. KPV is NOT currently on the WADA prohibited list. Compounded preparations vary in quality — third-party HPLC testing recommended.
KPV is NOT FDA-approved for any indication. Despite its small molecular size and clean side-effect profile, it has not progressed through formal clinical trials. Most evidence is from animal models (colitis, dermatitis) and cell-based research.
Anti-doping: KPV is NOT currently on the WADA prohibited list.
Compounded preparations vary in quality. Third-party HPLC testing recommended for any KPV product. Combined evidence base for KLOW blend is observational only.
Research-grade material is sold for laboratory use only and is not approved for human consumption.
KPV FAQ
Is KPV FDA-approved?
No. KPV is not FDA-approved for any indication. Despite its small molecular size, clean side-effect profile, and decades of research interest, it has not progressed through formal Phase 2 or 3 clinical trials. Most evidence is from animal models (colitis, dermatitis) and cell-based research.
How is KPV different from BPC-157?
Different mechanisms and primary applications. KPV is a 3-amino-acid tripeptide derived from α-MSH that acts intracellularly to inhibit NF-κB and reduce inflammatory cytokines. BPC-157 is a 15-amino-acid peptide that drives angiogenesis and tissue repair through nitric oxide and growth factor pathways. KPV is primarily anti-inflammatory; BPC-157 is primarily regenerative. They're commonly stacked together for gut applications because their mechanisms are complementary, not redundant.
Oral vs injectable vs topical — which is best?
Depends on application. Oral (enteric-coated capsules) is preferred for IBD/colitis because the peptide acts locally on intestinal mucosa. Subcutaneous injection produces systemic effects; useful for general anti-inflammatory protocols. Topical formulations target skin inflammation (atopic dermatitis, psoriasis research). Most users start oral for gut applications.
Does KPV cause tanning or sexual effects like Melanotan II / PT-141?
No. Despite being derived from α-MSH (the same parent hormone as Melanotan II and bremelanotide / PT-141), KPV does NOT activate melanocortin receptors. The 3-amino-acid fragment lacks the receptor-binding domain. KPV inhibits NF-κB signaling in cell studies, and in mouse colitis its effects were at least partly independent of MC1R signaling (Kannengiesser 2008).
Can I take KPV during a steroid taper?
KPV's anti-inflammatory effects are theoretically additive with corticosteroids. Some users use KPV adjunctively during steroid tapers to maintain inflammation control as steroid doses decrease. However, no controlled clinical data supports this protocol — discuss with the prescribing physician before adjusting steroid timing.
How does KLOW differ from KPV alone?
KLOW is a compounded blend combining KPV with GHK-Cu, BPC-157, and TB-500 (typical 50/10/10/10 mg ratio). It pairs KPV's anti-inflammatory effect with GHK-Cu's gene expression / collagen modulation and BPC-157 + TB-500's tissue repair. KPV alone is a more targeted anti-inflammatory; KLOW is a broader regenerative protocol.
Does KPV work for IBD/colitis?
Animal model evidence is strong. Multiple studies show KPV reduces colitis severity in DSS and TNBS-induced models — reduced histological damage, improved mucosal healing, decreased inflammatory infiltration. Particle-based delivery systems have been explored to target inflamed intestinal tissue. Human clinical trials in IBD have not been completed; community use suggests benefit but is observational.
Where can I buy KPV?
KPV is sold by specialty research peptide vendors as oral capsules, injectable lyophilized powder, or topical formulations. Compounded preparations vary in quality — third-party HPLC testing recommended. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .
References
- Brzoska T, Luger TA, Maaser C, et al. α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo. Endocr Rev. 2008;29(5):581-602. https://academic.oup.com/edrv/article/29/5/581/2355153
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. https://academic.oup.com/ibdjournal/article/14/3/324/4652783
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-9. https://academic.oup.com/jleukbio/article/67/2/233/4606432
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. https://www.gastrojournal.org/article/S0016-5085(07)01807-1/fulltext
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640.
- Wikipedia. Alpha-melanocyte-stimulating hormone. https://en.wikipedia.org/wiki/Alpha-melanocyte-stimulating_hormone
Published Studies
Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.
Brzoska T, Luger TA, Maaser C, Schiller M, Böhm M.
The foundational comprehensive review of alpha-MSH-derived peptides including KPV. The paper establishes the anti-inflammatory pharmacology of the C-terminal tripeptide and explains why KPV retains the anti-inflammatory activity of the parent hormone without the pigmentation effects.
Kannengiesser K, Maaser C, Heidemann J, et al.
This study established KPV's therapeutic potential in inflammatory bowel disease. Using DSS-induced colitis in mice, researchers showed that KPV significantly reduced colonic inflammation, improved histological healing scores, and decreased pro-inflammatory cytokine production.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al.
A mechanistic study examining how KPV enters intestinal epithelial cells. The researchers identified PepT1 as the primary uptake mechanism and demonstrated that this transport is upregulated during inflammation — effectively concentrating KPV at sites where it's needed.
Cutuli M, Cristiani S, Lipton JM, Catania A.
The first characterization of direct antimicrobial activity in KPV and related alpha-MSH fragments. Researchers found activity against both gram-positive and gram-negative bacteria as well as Candida albicans.
In the News
Related Peptides
Related Blends
Comparisons
We may earn commissions from peptide vendor affiliate links.
Have a question about KPV? Send us an email